
Loading, please wait...

Loading, please wait...

Primary immunodeficiency (PID) encompasses a diverse group of genetic disorders that severely compromise the immune system. A recent quantitative study highlights the significant primary immunodeficiency disease burden, emphasizing the diagnostic gaps and unmet needs facing this population. While therapeutic options like immunoglobulin therapy exist, many patients continue to experience persistent complications and a reduced quality of life.
The research findings reveal a mean diagnostic delay of three years, which significantly hinders timely clinical intervention. Consequently, nearly 79% of patients reported experiencing at least one misdiagnosis before receiving a correct PID identification. Furthermore, while 82% of respondents received immunoglobulin therapy, only a small fraction reported being complication-free. These statistics underline the clinical challenges despite available medical treatments.
Moreover, the study illustrates profound socioeconomic disruptions affecting both patients and families. For instance, educational activities were interrupted for over 25% of pediatric patients. In the adult cohort, unemployment affected 27% of individuals, while nearly half required frequent sick leave. Perhaps most significantly, the extensive caregiving demands forced over half of primary caregivers to resign from their jobs to provide dedicated support. Therefore, an integrated societal support system is essential for these families.
Integrated support systems should focus on earlier diagnosis and improved therapeutic access to mitigate the primary immunodeficiency disease burden. In addition, addressing the psychological and socioeconomic strain is vital for improving utility values, which currently remain lower than general population norms. Clinicians must recognize these broader impacts to provide comprehensive care for those living with PID.
The average diagnostic delay is approximately 3 years. However, nearly 45% of patients wait over one year, and many suffer from initial misdiagnosis or missed diagnosis before a final confirmation.
The burden on caregivers is extensive. According to research, over 50% of primary caregivers for pediatric PID patients eventually resign from their jobs to manage the intense caregiving demands.
Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Li L et al. Understanding the disease burden and unmet needs of patients with primary immunodeficiency in China: A quantitative study. Intractable Rare Dis Res. 2026 May 31. doi: 10.5582/irdr.2025.01074. PMID: 42221046.
Indian Society for Primary Immune Deficiency (ISPID). About PID in India. Available from: ispid.org.in.
Suri D, Rawat A, Singh S. Primary Immunodeficiency Disorders in India—A Situational Review. Front Immunol. 2017;8:714.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Recent data reveals significant primary immunodeficiency disease burden, including long diagnostic delays and severe socioeconomic impacts on patients....
4 months ago

A recent study demonstrates that spinal oxygen sensors do not require mitochondrial electron transport to trigger sympathetic excitation during acute hypoxia, revealing new insights into how mitochondrial oxidative stress modulates autonomic tone in cardiovascular and neurological diseases.
Today

Demanding exhaustive hormonal profiling can inadvertently discourage clinical studies involving females. Methodological standards must align with the specific scientific question to expand, not restrict, equitable evidence for women.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

A novel calcium polyphosphate coacervate enables injectable bone implants with in situ hierarchical porosity via phase separation and gas foaming, significantly enhancing cell proliferation, energy metabolism, and osteogenic differentiation for minimally invasive bone defect repair.
Today

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today